<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489319</url>
  </required_header>
  <id_info>
    <org_study_id>IU-PCOS-0112</org_study_id>
    <nct_id>NCT01489319</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)</brief_title>
  <acronym>ELI-ROAS</acronym>
  <official_title>Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relationship between lipid-induced inflammation
      and ovarian androgen secretion in women with polycystic ovary syndrome (PCOS); and to examine
      the effect of salsalate and polygonum cuspidatum extract (PCE) containing resveratrol on
      lipid-induced inflammation, ovarian androgen secretion, body composition and ovulation in a
      subset of normal weight women with PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator hypothesizes that in women with PCOS, HCG administration will stimulate an
      exaggerated ovarian androgen response, dairy cream ingestion will stimulate white blood cells
      to generate an inflammatory response, and that there is a relationship between HCG-stimulated
      ovarian androgen secretion and the inflammatory response to dairy cream ingestion regardless
      of body fat status. Thirty (30) women with PCOS (10 normal weight with normal abdominal
      adiposity, 10 normal weight with increased abdominal adiposity and 10 obese) and 30 ovulatory
      control women (10 normal weight with normal abdominal adiposity, 10 normal weight with
      increased abdominal adiposity and 10 obese) will participate over a 3-year period.

      The investigator also hypothesizes that both salsalate and PCE administration for 12 weeks
      will attenuate the ovarian androgen response to HCG administration and the inflammatory
      response to dairy cream ingestion, reduce abdominal adiposity, increase insulin sensitivity
      and induce ovulation in normal weight women with PCOS. A subset of 16 women with PCOS of
      which 8 will receive salsalate (4 normal weight with normal abdominal adiposity and 4 normal
      weight with increased abdominal adiposity) and 8 will receive PCE (4 normal weight with
      normal abdominal adiposity and 4 normal weight with increased abdominal adiposity) will
      participate in this intervention over a 3-year period. This pilot project will help determine
      the feasibility of conducting a larger double-blind, randomized trial in women with PCOS to
      further test the latter hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI left Indiana University. The findings served as preliminary data for a recently awarded
    NIH R01 grant.
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>White blood cell nuclear factor kappa B (NFkappaB) activation in response to oral lipid ingestion and ovarian androgen secretion in response to human chorionic gonadotropin (HCG) stimulation.</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome along with insulin sensitivity derived from an oral glucose tolerance test (OGTT) and body composition measured by dual energy absorptiometry (DEXA) will be assessed in all study subjects (PCOS and controls).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>White blood cell NFkappaB activation following oral lipid ingestion in response to 12 weeks of salsalate or PCE administration.</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome will be assessed in a subset of normal weight women with PCOS who have either normal (n=4) or increased (n=4) abdominal adiposity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian androgen secretion following HCG administration in response to 12 weeks of salsalate or PCE administration.</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome will be assessed in a subset of normal weight women with PCOS who have either normal (n=4) or increased (n=4) abdominal adiposity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition status measured by DEXA in response to 12 weeks of salsalate or PCE administration.</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome will be assessed in a subset of normal weight women with PCOS who have either normal (n=4) or increased (n=4) abdominal adiposity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity derived from an OGTT in response to 12 weeks of salsalate or PCE administration.</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome will be assessed in a subset of normal weight women with PCOS who have either normal (n=4) or increased (n=4) abdominal adiposity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovulation rates documented by serum progesterone in response to 12 weeks of salsalate or PCE administration</measure>
    <time_frame>3 years</time_frame>
    <description>This outcome will be assessed in a subset of normal weight women with PCOS who have either normal (n=4) or increased (n=4) abdominal adiposity.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Nl Wt PCOS - Nl Abdominal Adiposity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nl Wt PCOS - Increased Abdominal Adiposity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese PCOS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 obese women with PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nl Wt Controls - Nl Abdominal Adiposity</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nl Wt Controls - Increased Abdominal Adiposity</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 obese ovulatory women serving as controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.</description>
    <arm_group_label>Nl Wt PCOS - Nl Abdominal Adiposity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.</description>
    <arm_group_label>Nl Wt PCOS - Increased Abdominal Adiposity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Acceptable health based on interview, medical history, physical examination, and lab
             tests

          -  Ability to comply with the requirements of the study

          -  Ability and willingness to provide signed, witnessed informed consent

        Inclusion Criteria for PCOS:

          -  Between the ages of 18-40 years

          -  Body mass index between 18 and 25, or between 30 and 40

          -  Less than or equal to 8 periods annually

          -  An elevated serum androgen level or skin manifestations of androgen excess

          -  Normal thyroid function tests and normal prolactin level

          -  Exclusion of late-onset adrenal hyperplasia

        Inclusion Criteria for Ovulatory Controls:

          -  Between the ages of 18-40 years

          -  Body mass index between 18 and 25, or between 30 and 40

          -  Normal regular monthly periods

          -  No clinical evidence of androgen excess

          -  No evidence of polycystic ovaries on ultrasound

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Clinically significant pulmonary, cardiac ,renal, hepatic, neurologic, psychiatric,
             infectious, and malignant disease

          -  High blood pressure

          -  Current or recent (within 6 weeks prior to study entry) injection of any drugs known
             or suspected to affect reproductive function including oral contraceptives, metformin,
             thiazolidinediones, glucocorticoids, GnRH-agonists, or anti-androgens (spironolactone,
             flutamide, etc)

          -  Documented or suspected history of use of recent (within one year) illicit drug abuse
             or alcoholism

          -  Tobacco smoking if salsalate or PCE will be administered

          -  Ingestion of any investigational drugs within 4 weeks prior to study onset

          -  Pregnancy or lactation (less than or equal to 6 weeks postpartum)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Gonz√°lez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://obgyn.medicine.iu.edu/research/frank-gonz-lez-m-d/</url>
    <description>Indiana University Reproductive Endocrine and Inflammation Research Program</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Frank Gonzalez</investigator_full_name>
    <investigator_title>Associate Professor, Director, Division of Reproductive Endocrinology and Infertility</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>body composition</keyword>
  <keyword>hyperandrogenism</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

